Emcure Pharmaceuticals — 360° view

Emcure Pharmaceuticals, a company in the Pharmaceuticals industry, reported revenue of ₹2,820 crore and net profit of ₹325 crore for the September 2026 quarter.

Emcure Pharmaceuticals (NSE: EMCURE) closed at ₹2,337.80 on 20 Nov 2026, up 71.7% over the past year. Its market capitalisation is ₹44,351 crore and it trades at 39.9 times earnings.

Share price
₹2,337.80 (20 Nov 2026)
Market cap
₹44,351 Cr (20 Nov 2026)
P/E
39.88 (20 Nov 2026)
Revenue
₹2,820 Cr (September 2026 quarter)
Net profit
₹325 Cr (September 2026 quarter)
ROCE
24.0% (FY26)
ROE
20.1% (FY26)
Book value
₹282 (FY26)
Dividend yield
0.15% (last 12 months to 20 Nov 2026)
52-week high / low
₹2,429.90 / ₹1,312.30 (20 Nov 2026)
1-year return
71.7% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: EMCURE

Incorporated in 1981, Emcure Pharmaceuticals Ltd manufactures and markets pharmaceutical products globally

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.